September 17, 2020

BIO4AMB Trial Evaluates Biotronik’s 4-F Devices in Treating Ambulatory PAD

September 17, 2020—Biotronik announced that new clinical data from the BIO4AMB trial demonstrate that 4-F–compatible devices are a valid, safe option for endovascular treatment of ambulatory lower extremity peripheral artery disease and show similar results to 6-F devices, with the added benefit of eliminating the need for a vascular closure device.

The BIO4AMB multicenter controlled trial compared the rate of access site complications and major adverse events in 4-F versus 6-F femoral access endovascular interventions.

According to the company, the full-cohort analysis of 766 patients showed no significant differences in safety and efficacy between the patient group treated with 6-F devices and the group treated with Biotronik’s 4-F product portfolio. The portfolio includes the Pulsar-18 and Pulsar-18 T3 self-expanding stent systems, the Fortress reinforced introducer sheath system, the Passeo-18 Lux drug-coated balloon catheter, and the Passeo-18 percutaneous transluminal angioplasty balloon catheter.

Professor Marianne Brodmann, MD, presented the data at the Cardiovascular and Interventional Radiological Society of Europe’s CIRSE 2020 Summit held online September 12-15. Prof. Brodmann, who is with the Department of Angiology at the Medical University in Graz, Austria, serves as Coprincipal Investigator of the trial.

“Compared to the already well-established 6-F devices, 4-F–compatible devices were shown to be a valid alternative,” commented Prof. Brodmann in Biotronik’s announcement.

The rate of freedom from access site complications was 97.2% in the 4-F arm and 96.8% in the 6-F arm (P = .734). Prof. Brodmann highlighted a key difference, noting, “Use of 4-F sheaths creates 45% smaller puncture holes, which resulted in low rates of access site complications despite not needing vascular closure devices. This may offer a better potential for ambulatory treatment.”

Also, at CIRSE 2020, Coprincipal Investigator Professor Jos van den Berg, MD, presented findings from a health economic evaluation of the BIO4AMB study that investigated the implications on safety, resource use, and cost of lower extremity peripheral treatment using 4-F and 6-F access in an ambulatory setting. In this analysis, the rate of vascular closure device use was 0% in the 4-F arm versus 87.4% in the 6-F arm (P < .05).

“Depending on the country-specific reimbursement situation, ambulatory treatment may offer a cost-saving option compared to a stationary setting,” concluded Prof. van den Berg, who is Professor of Interventional Radiology at Ospedale Regionale di Lugano in Switzerland.


September 21, 2020

Robert W. Gore, Chairman Emeritus of W. L. Gore & Associates and Inventor of Gore-Tex, Dies at 83

September 17, 2020

RapidAI Gains Funding to Expand AI-Enhanced Cerebrovascular Imaging Products